KLRA — Kailera Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2096997 ·
Last close
$10.00
Market Cap
$1.30B
52W High
$28.23
52W Low
$9.76
ADV30
1,220,749
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -121,373,000 | -111,307,000 | 1,211,416,000 | 130,301,000 | 92,952,000 |
| Mar 2026 | 0 | — | -84,660,000 | -78,865,000 | 624,756,000 | 111,826,000 | 1,056,844,000 |
| Jun 2025 | 0 | — | -30,651,000 | -28,947,000 | — | — | — |
| Mar 2025 | 0 | — | -20,458,000 | -17,983,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-86,511,000
Investing CF
$-31,591,000
Financing CF
$-2,980,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.82
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-447,533,000
Inventory
—
Receivables
$3,208,000
ST Investments
$407,348,000
EBIT TTM
$-105,118,000
Pretax Income TTM
$-96,848,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -158,340,000 | -148,955,000 | 692,294,000 | 1,048,752,000 | -356,458,000 | -120,210,000 |
| Dec 2024 | — | — | — | 178,445,000 | 397,217,000 | -218,772,000 | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$624,756,000
Forward EPS
$-4.30
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DMRA | Damora Therapeutics, Inc. | $1.27B | $20.56 | — |
| KARD | Kardigan, Inc. | $1.33B | $14.20 | — |
| ORIC | Oric Pharmaceuticals, Inc. | $1.25B | $12.03 | — |
| AAPG | ASCENTAGE PHARMA GROUP INTERNATIONAL | $1.36B | $14.55 | — |
| ANAB | ANAPTYSBIO, INC | $1.37B | $46.21 | — |
News headlines (Yahoo Finance, 1h cache)
Kailera Therapeutics Presents New Clinical Data at EASD 2026 Annual Meeting
2026-10-01 10:45 · Yahoo
Kailera Therapeutics Completes Enrollment for Trial of Ribupatide to Treat Obesity
2026-09-30 11:44 · Yahoo
Kailera Therapeutics Announces Completion of Enrollment in KaiNETIC Global Phase 3 Clinical Program of GLP-1/GIP Receptor Dual Agonist Ribupatide Injection
2026-09-30 11:00 · Yahoo
Kailera Therapeutics to Participate in September Investor Conferences
2026-09-16 11:00 · Yahoo
Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”
2026-09-15 04:16 · Yahoo
Kailera Therapeutics: The Record-Breaking Obesity IPO Big Pharma Cannot Ignore
2026-08-18 14:10 · Yahoo
Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?
2026-08-17 13:10 · Yahoo
2 GLP-1 Stocks That Could Double Your Money by 2031
2026-08-16 20:20 · Yahoo
Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates
2026-08-12 20:05 · Yahoo
Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential
2026-07-10 13:58 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.